View profile

FarmaKology Newsletter - Issue #41

Revue
 
Would you like to submit an article, some interesting news, or get your startup featured? Send whatev
 

FarmaKology

April 10 · Issue #41 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+4100 Subscribers ) !

Today's Startup
Alector
Alector ,We are pioneers.We are unified around a common goal of creating disruptive change in the way the world treats neurodegenerative disorders. is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.
News
As the nation’s leading voluntary lung health organization, the American Lung Association is launching a $25M initiative to end COVID-19 and defend against future respiratory virus pandemics. The COVID-19 Action Initiative will be used to expand the Association’s ongoing respiratory research program, enhance key public health measures, and establish an advanced network to stop future respiratory virus pandemics.
Apple and Google are jointly building software into iPhone and Android devices to help track the spread of coronavirus by telling users if they contacted an infected person and are potentially sick themselves. The new project is slated for release in May.
Darmiyan, Inc. is pleased to announce the initial closing of a $6M Series Seed investment round led by the pharmaceutical giant Eisai, creating a major business collaboration opportunity between the two companies, one focused on advanced brain diagnostics, and the other focused on Alzheimer’s therapeutics. IT-Farm and Y-Combinator (YC) also participated in the round.
Chinas’s CanSino Biologics is advancing its COVID-19 vaccine candidate into Phase II, putting the company ahead of others in the race against the novel coronavirus.In a filing with the Hong Kong Securities Exchange on Thursday, the company said that based on preliminary safety data from its Phase I clinical trial for a Recombinant Novel Coronavirus Disease Vaccine, the company is planning to initiate a mid-stage trial in China soon.
Research & Study
Podcast
Episode 106: Privacy in a pandemic, biopharma's big opportunity, and Shkreli's plea for a break by STAT | Free Listening on SoundCloud
Job Opportunities
Video
The Coronavirus Explained & What You Should Do
FarmaKology
FarmaKology
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue